Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World January 6, 2011 Laura Howes	Using HIV against itself US researchers have developed a 'Trojan horse' molecule that uses HIV to trigger the release of a drug that destroys the virus.
Popular Mechanics December 1, 2006 Ben Harder	Fighting HIV by Building a New Killer In the fight to find a cure for AIDS, researchers have invented a viral double agent on a mission to seek out where HIV hides.
Chemistry World November 27, 2008 Lewis Brindley	Bryostatin Synthesis Made Simple US chemists have dramatically shortened the synthesis of byrostatin 16, one of a family of natural products that show promising activity against cancer but can't easily be extracted from nature or made artificially.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
Chemistry World August 1, 2013 James Urquhart	Total synthesis outshines biotech route to anticancer drug US scientists have developed the first efficient and scalable route for the total synthesis of ingenol -- a plant-derived diterpenoid used to treat precancerous skin legions.
Pharmaceutical Executive December 1, 2005 Alana Klein	Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance.
BusinessWeek September 2, 2010 Simeon Bennett	David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS.
Chemistry World November 6, 2009 Simon Hadlington	Boron-based compounds inhibit key HIV enzyme Researchers in the Czech Republic have shown that an unusual class of boron-containing compound can inhibit HIV protease, a key enzyme involved in replicating the virus that causes Aids.
Chemistry World August 4, 2008 Pete Mitchell	Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate.
BusinessWeek February 10, 2011 Rob Waters	Sangamo's Bet Against AIDS: Gene Therapy Sangamo's stock has more than doubled since July 6, when the company, with no products on the market, reported success of its gene therapy approach in mice in the journal Nature Biotechnology.
Chemistry World December 13, 2007 Lewis Brindley	Semen Protein Raises HIV Infection Risk Scientists have identified a protein in human semen that increases the risk of HIV infection up to 100,000 fold. The discovery could provide new drug targets and strategies for combating the global AIDS epidemic.
The Motley Fool June 21, 2011 Frank Vinluan	GSK HIV Drug Pipeline Sees Boost as Partner Concert Steers to Clinical Trials GSK and Concert have a possible new treatment for HIV.
Chemistry World March 10, 2008 Victoria Gill	New Hope for Anti-HIV Gels Early data from a clinical trial has rekindled hope of an effective topical gel to prevent HIV infection.
Chemistry World August 2007 Derek Lowe	Opinion: In the Pipeline Process chemists just don't get the credit they deserve.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
Chemistry World September 26, 2007 Victoria Gill	HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed.
The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
BusinessWeek November 24, 2003 John Carey	Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells.
American Journal of Nursing March 2010 David E. Vance	Aging with HIV: Clinical Considerations for an Emerging Population Since the advent of highly active antiretroviral therapy, HIV infection has become a chronic, albeit life-threatening, condition that can be managed; therefore, more and more people are growing older with HIV.
American Journal of Nursing March 2010 Bradley-Springer et al.	Every Nurse Is an HIV Nurse The evolution of HIV infection into a chronic disease has implications across all clinical care settings. Every nurse should be knowledgeable about the disease in order to provide high-quality care to people with or at risk for HIV.
Chemistry World May 20, 2015 Katrina Kramer	Taking the lead on drug discovery Researchers from the UK have developed a straightforward strategy for making compounds that have the potential to become clinical drugs.
The Motley Fool April 3, 2008 Brian Lawler	A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
Chemistry World March 2011	60 years of innovation To celebrate the international year of chemistry, James Mitchell Crow looks back at some of the discoveries and developments made by chemists over the past six decades
Chemistry World January 3, 2012 Simon Hadlington	One-pot synthesis creates anticancer candidates Researchers in Germany have developed a simple, rapid and high-yielding cascade synthesis of a collection of polycyclic compounds that resemble indole alkaloid natural products and which interfere with cell division.
BusinessWeek April 1, 2010 Bennett & Randall	Will an AIDS Pill a Day Keep the Virus Away? Drugmaker Gilead is betting the one-pill PrEP treatment will slow the virus' spread - as are some of the world's top health agencies and philanthropists.
Chemistry World February 9, 2007 Victoria Gill	Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo.
Chemistry World June 11, 2008 James Mitchell Crow	New Hope for Anticancer Agent The mode of action of a rare natural product with promising cytotoxic activity has been revealed by scientists in the US while a UK group have come up with a particularly efficient chemical synthesis.
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World September 24, 2015	A new hope in HIV prevention New microbicide products could turn the tide against Aids for those who need it most: women in sub-Saharan Africa. Dinsa Sachan reports.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
Chemistry World April 27, 2007 Ned Stafford	New HIV Blocker Prepares for Trials Scientists who isolated a natural component of human blood that defends against the HIV-1 virus are now moving quickly to test their ideas clinically in the hope of bringing a new class of HIV-blockers based on peptide therapeutics to market.
Scientific American October 2008 John Rennie	Hope and the Fight against HIV The battle must continue, even if 25 years of research have disappointed.
Chemistry World September 17, 2009 Ned Stafford	Food supplement fights HIV A medical nutritional supplement can slow the decline in immunity in HIV-positive patients, according to clinical trials results presented this week.
The Motley Fool June 26, 2008 Brian Lawler	Ardea Takes the More Exciting Route Ardea Bioscicences announces phase 2a data for its lead anti-HIV drug that is good enough to encourage further testing.
Chemistry World June 6, 2013 Jennifer Newton	Power-free nucleic acid extraction device HIV RNA has been successfully extracted from human blood using a portable device that does not need electrical power to work.
Bio-IT World August 18, 2004 Kevin Davies	In Praise of Chemical Diversity How to build better small-molecule libraries.
American Family Physician July 15, 2004 Joel E. Gallant	HIV Counseling, Testing, and Referral By the year 2005, the CDC seeks to achieve the following: reduce annual new HIV infections from the current estimated 40,000 cases to 20,000 cases through the use of interventions such as counseling, HIV testing, and referral
Chemistry World April 2011	Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.
BusinessWeek September 12, 2005 John Carey	A Better Way To Ambush AIDS? HIV increasingly outwits today's drugs even as side effects take a toll. But Panacos Pharmaceuticals' experimental drug opens the door to a new line of attack.
Chemistry World December 1, 2014 Derek Lowe	Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture.
American Family Physician January 1, 2001 Alex H. Krist	Obstetric Care in Patients with HIV Disease Appropriate management of pregnant patients who have human immunodeficiency virus (HIV) disease can have a major impact on maternal and infant health...
Salon.com July 28, 2000 Kate Scanell	Contributing to genocide By giving HIV deniers a global platform, South African President Mbeki has put countless lives at risk.
American Family Physician August 1, 2000 Sharon Scott Morey	Practice Guidelines HHS Updates Guidelines for Antiretroviral Therapy in HIV Infection
Nursing January 2011 Carl A. Kirton	HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness.
Chemistry World May 23, 2011 James Mitchell Crow	Hatching a plan to kill worm pests A parasitic pest that can devastate entire fields of vegetable crops is a step closer to being brought under control, thanks to the synthesis of a compound that tricks its eggs into hatching early.
American Family Physician January 15, 2006 Ann M. Khalsa	Preventive Counseling, Screening, and Therapy for the Patient with Newly Diagnosed HIV Infection The epidemic of HIV continues, and the infection is converting into a treatable chronic disease; therefore, it is increasingly important for family physicians to be current with and comfortable in providing basic care to patients infected with HIV.
BusinessWeek October 20, 2003 Gene G. Marcial	How Immune Response Targets AIDS Immune Response's Remune is aimed at slowing the advance of HIV and delaying the need for antiretroviral drugs, which have toxic effects. A look at the company's situation and its stock.
American Family Physician February 1, 2001 Eleftherios Mylonakis	Plasma Viral Load Testing in the Management of HIV Infection In the 1990s, new technologies, including the polymerase chain reaction assay, the branched DNA assay and the nucleic acid sequence-based amplification assay, made it possible to obtain accurate quantitative measurements of human immunodeficiency virus (HIV) RNA in plasma...
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.